GO
Loading...

Enter multiple symbols separated by commas

Drug Retail

More

  • Tekmira soars on FDA news   Monday, 22 Sep 2014 | 2:05 PM ET
    Tekmira soars on FDA news

    Tekmira said regulators in the U.S. and Canada authorized use of its experimental drug for Ebola through an expanded access program. CNBC's Meg Tirrell provides insight.

  • High at work   Thursday, 18 Sep 2014 | 1:54 PM ET
    High at work

    A new survey from Mashable finds nearly 10 percent of Americans admit to smoking pot before heading into the office. CNBC's Kate Rogers shares the difficulties in testing employees.

  • Avanir up on Alzheimer's trial   Monday, 15 Sep 2014 | 1:03 PM ET
    Avanir up on Alzheimer's trial

    Avanir Pharma is up more than 60 percent, after the company said its drug was more effective in reducing agitation associated with Alzheimer's, compared with a placebo. CNBC's Meg Tirrell speaks to the company's CEO Keith Katkin.

  • Orexigen's obesity pill   Thursday, 11 Sep 2014 | 1:11 PM ET
    Orexigen's obesity pill

    Orexigen's obesity pill is called Contrave, and it's been approved in the U.S. CNBC's Meg Tirrell reports.

  • Food prices hit 4-year low, Russia ban hurts Thursday, 11 Sep 2014 | 8:20 AM ET

    The UN food price index has dipped to a four-year low as good weather has resulted in an oversupply of cereals and dairy imports have slowed.

  • Walgreen adds activist hedge fund founder to board Monday, 8 Sep 2014 | 7:57 AM ET
    Barry Rosenstein, founder and managing partner of Jana Partners

    Walgreen is naming Jana founder Rosenstein to its board and the activist investor will get a say in choosing at least one additional director.

  • Big change for pain drugs   Friday, 22 Aug 2014 | 2:12 PM ET
    Big change for pain drugs

    CNBC's Meg Tirrell reports the Drug Enforcement Administration is changing the rules around pain drugs like Vicodin. The drugs will be deemed "schedule 2 substances," versus the less restrictive "schedule 3."

  • Obesity treatment sales fall short   Monday, 18 Aug 2014 | 6:26 AM ET
    Obesity treatment sales fall short

    CNBC's Meg Tirrell provides insight to the definition of obesity by the CDC, and which drug companies are working on treatments in the space.

  • Forest fire threatens illegal marijuana grows   Thursday, 14 Aug 2014 | 1:29 PM ET
    Forest fire threatens illegal marijuana grows

    A massive fire in Northern California has so far burned close to 12,000 acres and injured 12 people. CNBC's Jane Wells reports on the costs to the state, as well as to marijuana growers.

  • Ebola not easily spread: Doctor   Thursday, 7 Aug 2014 | 3:19 PM ET

    Dr. Beth Bell, CDC Infectious Diseases Center, discusses the Ebola crisis in West Africa, and the risks to U.S. citizens. Bell explains current experimental treatments.

  • Pharma companies rush to help Ebola   Thursday, 7 Aug 2014 | 2:17 PM ET
    Pharma companies rush to help Ebola

    The CDC Director is testifying before Congress on Ebola, and pharma companies are scrambling to create drugs to help. CNBC's Meg Tirrell, and Michael Yee, RBC Capital Markets, discuss some of these companies.

  • Will generic Viagra transform China? Tuesday, 5 Aug 2014 | 6:21 PM ET

    Viagra's patent in China has expired and some analysts expect cheaper prices will bring a surge of demand for the storied erectile dysfunction drug.

  • The push back on Sovaldi   Friday, 25 Jul 2014 | 2:52 PM ET
    The push back on Sovaldi

    Insurance companies are hurting from the high cost of hepatitis C drug Sovaldi. Arthur Caplan, NYU Langone Medical Center, and CNBC's Bertha Coombs, share their opinions.

  • The $84,000 drug debate   Friday, 25 Jul 2014 | 2:50 PM ET
    The $84,000 drug debate

    CNBC's Bertha Coombs reports which insurance stocks are hurting from the high cost of hepatitis C Sovaldi.

  • Drug costs hit insurers: Gilead still a buy?   Friday, 25 Jul 2014 | 12:15 PM ET
    Drug costs hit insurers: Gilead still a buy?

    CNBC's Bertha Coombs reports which insurance stocks are feeling the pressure from high drug costs. FMHR trader Stephen Weiss advises investors to stick with Gilead.

  • FedEx indicted for prescription roulette   Friday, 18 Jul 2014 | 1:53 PM ET
    FedEx indicted for prescription roulette

    CNBC's Scott Cohn reports FedEx has been indicted on 15 criminal counts for helping Internet pharmacies deliver drugs to buyers in the U.S. without prescriptions.

  • Next global epidemic?   Tuesday, 15 Jul 2014 | 1:40 PM ET
    Next global epidemic?

    CNBC's Meg Tirrell reports which biotech companies are working on what analysts say could be the next big biotech catalyst known as NASH, or nonalcoholic steatohepatitis.

  • Financing legal pot   Tuesday, 8 Jul 2014 | 4:50 PM ET
    Financing legal pot

    David Dinenberg, Kind Banking founder and CEO, provides insight to his business model of providing financing to the new legal pot industry.

  • Wild ride for MannKind's Afrezza   Monday, 30 Jun 2014 | 1:12 PM ET
    Wild ride for MannKind's Afrezza

    The FDA approved MannKind's inhaled insulin drug Afrezza. CNBC's Meg Tirrell has the details of the approval.

  • Pot start-ups pitch to angel investors   Monday, 23 Jun 2014 | 2:41 PM ET
    Pot start-ups pitch to angel investors

    Paid members of the Arcview Group have committed to investing at least $50,000 into the budding cannabis industry. Members are in Denver hearing pitches from pot start-ups, reports CNBC's Josh Lipton.